Tag: safety

LOS ANGELES, July 23, 2025 /PRNewswire/ -- Viewers of Public Television are in for an enlightening experience as "Empowered with Meg Ryan" presents a...

KOLKATA, India, July 23, 2025 /PRNewswire/ -- Himadri Speciality Chemical Ltd, a global frontrunner in advanced materials and sustainable chemical solutions, has been named...

Basecase is for RAN to Stay Flat REDWOOD CITY, Calif., July 23, 2025 /PRNewswire/ -- According to a newly published forecast report by Dell'Oro Group,...

ZUG, Switzerland, July 22, 2025 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris,” Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), announced today the pricing of an underwritten offering of (i) 8,250,000 of its ordinary shares at a price of $20.00 per share and (ii) to one investor, pre-funded warrants to purchase 500,000 ordinary shares at a price of $19.99 per pre-funded warrant, which represents the per share public offering price for the ordinary shares less the $0.01 per share exercise price for each such pre-funded warrant. All shares and pre-funded warrants in the offering are to be sold by Pharvaris. In addition, Pharvaris has granted the underwriters a 30-day option to purchase up to an additional 1,312,500 ordinary shares at the public offering price, less underwriting discounts and commissions. The gross proceeds to Pharvaris from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $175 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on or about July 24, 2025, subject to satisfaction of customary closing conditions.

SINGAPORE, July 23, 2025 /PRNewswire/ -- On 17 July 2025, Giti Tire was honoured to be conferred as a 3 heart Company of Good at...

ASX Release $132M Treasury Build in Q4 FY25 PERTH, Western Australia, July 23, 2025 /CNW/ - Westgold Resources Limited (ASX | TSX: WGX - Westgold or the Company) is pleased to report results...

CALGARY, AB, July 22, 2025 /CNW/ - Western Energy Services Corp. ("Western" or the "Company") (TSX: WRG) announces the release of its second quarter...

The ROR inhibitors market is witnessing steady growth driven by the increasing understanding of receptor tyrosine kinase-like orphan receptor (ROR) pathways in cancer and...

The ROR inhibitors market is witnessing steady growth driven by the increasing understanding of receptor tyrosine kinase-like orphan receptor (ROR) pathways in cancer and...

Eupraxia Pharmaceuticals Invited to Present at Upcoming Investor Conferences

CALGARY, AB, July 22, 2025 /CNW/ - Parkland Corporation ("Parkland", "we", the "Company", or "our") (TSX: PKI) expects to announce its 2025 second quarter...